Literature DB >> 8294861

Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.

D J Peace1, J W Smith, W Chen, S G You, W L Cosand, J Blake, M A Cheever.   

Abstract

Ras protooncogenes are activated by characteristic point mutations in a wide variety of malignancies. The expressed p21ras proteins are oncogenic by virtue of single substituted amino acids, usually at position 12 or 61 of the 189-residue p21ras protein. In the current study, the ability of class I major histocompatibility complex (MHC)-restricted T cells to recognize the altered segment of a transforming p21ras protein and to lyse cells transformed by the corresponding ras oncogene was examined. Synthetic ras peptides encompassing the common activating substitution of leucine for glutamine at position 61 were constructed with an amino acid motif appropriate for binding to the H-2Kb murine class I MHC molecule. Cytotoxic T lymphocytes (CTL) specific for bound ras leucine 61 peptide were elicited by in vitro immunization of normal lymphocytes with synthetic peptides. The ras peptide-induced CTL specifically lysed syngeneic fibroblasts transformed by an activated ras gene encoding oncogenic p21ras protein containing the same single amino acid substitution. Thus, in some circumstances, mutated p21ras protein can serve as a tumor-specific antigen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8294861      PMCID: PMC2191373          DOI: 10.1084/jem.179.2.473

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  32 in total

1.  Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb.

Authors:  D H Fremont; M Matsumura; E A Stura; P A Peterson; I A Wilson
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

2.  Emerging principles for the recognition of peptide antigens by MHC class I molecules.

Authors:  M Matsumura; D H Fremont; P A Peterson; I A Wilson
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

3.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

4.  Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.

Authors:  G Y Ishioka; S Colon; C Miles; H M Grey; R W Chesnut
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

5.  Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis.

Authors:  P Q Patek; J L Collins; M Cohn
Journal:  Nature       Date:  1978-11-30       Impact factor: 49.962

6.  A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.

Authors:  M Yanuck; D P Carbone; C D Pendleton; T Tsukui; S F Winter; J D Minna; J A Berzofsky
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

7.  Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.

Authors:  R G Fenton; D D Taub; L W Kwak; M R Smith; D L Longo
Journal:  J Natl Cancer Inst       Date:  1993-08-18       Impact factor: 13.506

8.  Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition.

Authors:  W Zhang; A C Young; M Imarai; S G Nathenson; J C Sacchettini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

9.  Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo.

Authors:  S Raychaudhuri; M Tonks; F Carbone; T Ryskamp; W J Morrow; N Hanna
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

10.  Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.

Authors:  J Skipper; H J Stauss
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

2.  Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas.

Authors:  An-hua Wu; Jing Xiao; Lars Anker; Walter A Hall; Dale S Gregerson; Webster K Cavenee; Wei Chen; Walter C Low
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 3.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

Review 4.  Vaccine therapy for cancer.

Authors:  D C Linehan; P S Goedegebuure; T J Eberlein
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

5.  Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.

Authors:  K R Irvine; B J McCabe; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

Review 6.  The role of the immune system in anti-tumour responses. Potential for drug therapy.

Authors:  S Dermime; J Barrett; C Gambacorti-Passerini
Journal:  Drugs Aging       Date:  1995-10       Impact factor: 3.923

7.  Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.

Authors:  B J McCabe; K R Irvine; M I Nishimura; J C Yang; P J Spiess; E P Shulman; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

Review 8.  Targeting pediatric malignancies for T cell-mediated immune responses.

Authors:  C L Mackall; L J Helman
Journal:  Curr Oncol Rep       Date:  2000-11       Impact factor: 5.945

9.  Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.

Authors:  J Blake; J V Johnston; K E Hellström; H Marquardt; L Chen
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

10.  Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein.

Authors:  C T Siegel; K Schreiber; S C Meredith; G B Beck-Engeser; D W Lancki; C A Lazarski; Y X Fu; D A Rowley; H Schreiber
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.